CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 6 enrolled
Drug / intervention
Radio-Frequency Ablation (RFA)procedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02328807
NCT02328807N/ACompleted
CompareCT.gov

Focal Prostate Radio-Frequency Ablation for the Treatment of Prostate Cancer

H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted Dec 31, 2014·Updated Aug 6, 2021

In Brief

A clinical study evaluating Radio-Frequency Ablation (RFA) for Prostate Cancer. Completed, enrolled 6 participants across 1 site.

Detailed Summary

The main purpose of this study is to evaluate the safety and efficacy of focal (targeted) Radio-Frequency Ablation (RFA) in men with low or intermediate-risk, clinically localized prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsTrod Medical N.V.

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 31, 2014
Enrollment StartDec 29, 2014
Primary CompletionMay 10, 2018
Study CompletionJul 8, 2021
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 11.5 years ago

Interventions

Radio-Frequency Ablation (RFA)procedure

RFA is a minimally invasive procedure. It is an image-guided technique that heats and destroys cancer cells. In RFA, imaging techniques such as ultrasound or magnetic resonance imaging (MRI) are used to help guide a needle electrode into a cancerous tumor. High-frequency electrical currents are then passed through the electrode, destroying the cancer cells.